Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk

Loss of imprinting (LOI), an epigenetic alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa of about 30% of colorectal cancer (CRC) patients, but it is found in only 10% of healthy individuals. In a pilot study to investigate the utility of LOI as a marker of CRC risk, we evaluated 172 patients at a colonoscopy clinic. The adjusted odds ratio for LOI in lymphocytes was 5.15 for patients with a positive family history [95% confidence interval (95% CI), 1.70 to 16.96; probability P = 0.002], 3.46 for patients with adenomas (95% CI, 1.14 to 11.37; P = 0.026), and 21.7 for patients with CRC (95% CI, 3.48 to 153.6; P = 0.0005). LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker of an individual's risk for CRC.

[1]  M. Khoury,et al.  Population screening in the age of genomic medicine. , 2003, The New England journal of medicine.

[2]  A. Feinberg,et al.  Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. , 2002, Cancer research.

[3]  D. Ahnen,et al.  Basic concepts for genetic testing in common hereditary colorectal cancer syndromes , 2002 .

[4]  A. Feinberg,et al.  Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. , 2001, Journal of the National Cancer Institute.

[5]  P. Peltomäki,et al.  Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Leppert,et al.  The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. , 2001, Gastroenterology.

[7]  B. Tycko,et al.  Epigenetic heterogeneity at imprinted loci in normal populations. , 2001, Biochemical and biophysical research communications.

[8]  A. Feinberg,et al.  Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability , 1998, Nature Medicine.

[9]  S. Baylin,et al.  Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Haddada,et al.  IGF‐2 autocrine stimulation in tumorigenic clones of a human colon‐carcinoma cell line , 1995, International journal of cancer.

[11]  J. Marvaldi,et al.  Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line. , 1992, Cancer research.

[12]  L. Suardet,et al.  Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. , 1992, British Journal of Cancer.

[13]  J. Vassalotti,et al.  Insulin-like growth factor-II: possible local growth factor in pheochromocytoma. , 1990, The Journal of clinical endocrinology and metabolism.

[14]  E. Kohn,et al.  Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[15]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[16]  D. Yee,et al.  Insulin-like growth factor II mRNA expression in human breast cancer. , 1988, Cancer research.